WT1 and acute myeloid leukemia: As shown in Figures 3C, D, for AML patients with both WT1 mutations and positive FLT3/ITD, 5-year EFS (33.3 ± 19.2%) and OS (50.0 ± 20.4%) were higher in children with HSCT than those with chemotherapy-only (EFS: 0.0 ± 0.0%, P=0.152; OS: 17.3 ± 11.1%, P=0.205), respectively, although the differences between the two groups were not statistically significant.